MavacamtenValsalvaNT pro-BNPNT-pro BNPNICESix-Minute Walk Testhypertrophic cardiomyopathy
…ic therapies designed to target the underlying pathophysiology. Mavacamten, a first-in-class cardiac myosin inhibitor, received approval i…
8articles mentioning drugs
38drug mentions
1distinct drugs extracted
0%of mentions human-reviewed
Active filtersEntity: mavacamten ×
mavacamten
This drug is selected. Its supporting articles are shown below.
Articles mentioning mavacamten
8 articles · page 1 of 1MavacamtenSix-Minute Walk TestNICEBelfast Inherited Cardiac Services CentreoHCMsymptomatic obstructive hypertrophic cardiomyopathy
…Introduction Mavacamten, a first-in-class cardiac myosin inhibitor, received NICE appro…
Mavacamtenhypertrophic cardiomyopathyHCMnHCMoHCM
…ross both phenotypes, confirming biological activity.Conclusion Mavacamten appears effective in oHCM, improving symptoms and obstruction w…
mavacamtenhypertrophic obstructive cardiomyopathy (HOCM)German tertiary referral centre
…t ventricular hypertrophy (LVH) in patients with HOCM receiving mavacamten therapy.Methods In this retrospective study, after screening of…
MavacamtenomeprazoleHypertrophic obstructive cardiomyopathy (HOCM)
…bling symptoms, and an increased risk of cardiovascular events. Mavacamten, a selective cardiac myosin modulator, has demonstrated improve…
MavacamtenObstructive Hypertrophic CardiomyopathyChinese Healthcare SystemMBC regimenPBC regimenEXPLORER-HCM
…g changes in the ICER value.Conclusion This study confirms that Mavacamten provides substantial health benefits to patients, but its relat…
mavacamtenaficamtenOMhypertrophic cardiomyopathyheart failureinherited heart disease
…linking mass spectrometry. We also explore the effectiveness of mavacamten as a myosin inhibitor in the presence of specific disease-causi…
mavacamtenhypertrophic cardiomyopathyinfective endocarditisTriNetX research network
…1). In an exploratory subgroup of 231 HCM patients treated with mavacamten, no IE cases occurred during the 1-year follow-up period.Conclu…